文献速递泌尿生殖与妇科肿瘤放疗姑息放疗与转移瘤

去势抵抗性寡转移前列腺癌的转移灶导向放疗:法国COLib组的多中心回顾性研究

Metastases-directed radiotherapy in castration resistant oligo metastatic prostate cancer: A multicentric retrospective study from the French group COLib.
PubMed 文献 · Clin Transl Radiat Oncol · 2024-03-17

该多中心回顾性研究纳入8家法国放疗中心的107例去势抵抗性寡转移前列腺癌患者,共对197个转移灶行转移灶导向消融放疗(MDRT)。

核心结论

  • PSA倍增时间(PSADT)长于6个月可能与更好的PFS相关。
  • MDRT策略可能推迟开始新的系统性治疗,中位PFS>1年。

研究设计与样本

  • 法国COLib组开展的多中心回顾性研究,回顾性分析了8家法国高容量放疗中心接受MDRT的去势抵抗性寡转移前列腺癌病例。
  • 共纳入107例患者,其中197个转移灶接受了MDRT。
  • OS定义为MDRT第一天至死亡的时间,PFS定义为MDRT第一天至按PCWG标准判定的进展时间,采用Kaplan-Meier法评估并以log rank检验比较曲线。
  • 采用逻辑回归分析结局预测因素:骨转移 vs 淋巴结转移、ISUP分级、MDRT时PSADT、至去势抵抗时间。

关键数值与推荐

  • 寡转移定义为可检测到的转移灶数量≤5个。
  • 未发现ISUP分级(1-2 vs 3-4-5)与PFS相关,也未发现激素敏感持续时间与PFS相关。

临床怎么用

  • 原文结论未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Oligometastases are defined as a number of detectable metastases less or equal to 5. In castrate-resistant oligo metastatic prostate Cancer (CR oligoM PC), Metastases-Directed Ablative radiotherapy (MDRT) is poorly investigated. Our study retrospectively reviewed the cases of CR oligoM PC treated with MDRT in 8 French high-volume radiotherapy centers. OS and PFS are defined as the delay between the first day of MDRT and death (OS) or progression according to PCWG criteria (PFS). OS and PFS are evaluated according to Kaplan Meyer, curves are compared with log rank test. Logistic regression was used to identify predictive factors for outcome: bone versus node metastasis, ISUP grade, PSA doubling Time (PSADT) at the time of MDRT, time to castration resistance. 107 patients were included in the study, among those 197 metastases received MDRT. For the overall population, the median follow-up was 25.2 months (1,4-145). OS was 93 % at 2 years and 81,4% at 3 years. At 2 years, 100 % of patients with node-only metastasis were alive versus 88,7% among those who have bone metastases (p = 0,72). The median PFS was 12,6 months (IC 95 % [9,6; 17]), with no difference among patients with node only disease versus the rest of the cohort. The PFS was 18,2 months (10,0; 32,4) in patients with PSADT >6 months versus 10,7 months (8,9; 14,3) when PSADT was inferior to 6 months. However, this difference did not reach significant. We did not find a correlation neither between ISUP grade (1-2 versus 3-4-5) and PFS, nor between hormone-sensitivity duration and PFS. Patients receiving MDRT for CR oligoM PC have a good prognosis with 81,6% OS at 3 years. PSA DT longer than 6 months could be related to better PFS. MDRT strategy could postpone the onset of new systemic treatment with median PFS >1 year.

来源:Clin Transl Radiat Oncol,查看原文。版权归原作者所有。

引用

  1. Chamois J, Septans AL, Schipman B, et al. Metastases-directed radiotherapy in castration resistant oligo metastatic prostate cancer: A multicentric retrospective study from the French group COLib. Clin Transl Radiat Oncol. 2024. PMID: 38572302. doi:10.1016/j.ctro.2024.100762

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。